• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在识别非酒精性脂肪性肝病(NAFLD)及NAFLD相关肝硬化的临床显著阶段方面,机器学习模型优于非侵入性检测。

Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis.

作者信息

Chang Devon, Truong Emily, Mena Edward A, Pacheco Fabiana, Wong Micaela, Guindi Maha, Todo Tsuyoshi T, Noureddin Nabil, Ayoub Walid, Yang Ju Dong, Kim Irene K, Kohli Anita, Alkhouri Naim, Harrison Stephen, Noureddin Mazen

机构信息

Arnold O. Beckman High School , Irvine , California , USA.

Department of Medicine , Cedars Sinai Medical Center , Los Angeles , California , USA.

出版信息

Hepatology. 2023 Feb 1;77(2):546-557. doi: 10.1002/hep.32655. Epub 2022 Aug 9.

DOI:10.1002/hep.32655
PMID:35809234
Abstract

BACKGROUND AND AIMS

We assessed the performance of machine learning (ML) models in identifying clinically significant NAFLD-associated liver fibrosis and cirrhosis.

APPROACH AND RESULTS

We implemented ML models including logistic regression (LR), random forest (RF), and artificial neural network to predict histological stages of fibrosis using 17 demographic/clinical features in 1370 patients with NAFLD who underwent liver biopsy, FibroScan, and labs within a 6-month period at multiple U.S. centers. Histological stages of fibrosis (≥F2, ≥F3, and F4) were predicted using ML, FibroScan liver stiffness measurements, and Fibrosis-4 index (FIB-4). NASH with significant fibrosis (NAS ≥ 4 + ≥F2) was assessed using ML, FibroScan-AST (FAST) score, FIB-4, and NAFLD fibrosis score (NFS). We used 80% of the cohort to train and 20% to test the ML models. For ≥F2, ≥F3, F4, and NASH + NAS ≥ 4 + ≥F2, all ML models, especially RF, had primarily higher accuracy and AUC compared with FibroScan, FIB-4, FAST, and NFS. AUC for RF versus FibroScan and FIB-4 for ≥F2, ≥F3, and F4 were (0.86 vs. 0.81, 0.78), (0.89 vs. 0.83, 0.82), and (0.89 vs. 0.86, 0.85), respectively. AUC for RF versus FAST, FIB-4, and NFS for NASH + NAS ≥ 4 + ≥F2 were (0.80 vs. 0.77, 0.66, 0.63). For NASH + NAS ≥ 4 + ≥F2, all ML models had lower/similar percentages within the indeterminate zone compared with FIB-4 and NFS. Overall, ML models performed better in sensitivity, specificity, positive predictive value, and negative predictive value compared with traditional noninvasive tests.

CONCLUSIONS

ML models performed better overall than FibroScan, FIB-4, FAST, and NFS. ML could be an effective tool for identifying clinically significant liver fibrosis and cirrhosis in patients with NAFLD.

摘要

背景与目的

我们评估了机器学习(ML)模型在识别具有临床意义的非酒精性脂肪性肝病(NAFLD)相关肝纤维化和肝硬化方面的性能。

方法与结果

我们实施了包括逻辑回归(LR)、随机森林(RF)和人工神经网络在内的ML模型,使用1370例在美国多个中心接受肝活检、FibroScan检查和实验室检查的NAFLD患者的17种人口统计学/临床特征来预测纤维化的组织学阶段。使用ML、FibroScan肝脏硬度测量值和Fibrosis-4指数(FIB-4)预测纤维化的组织学阶段(≥F2、≥F3和F4)。使用ML、FibroScan-天门冬氨酸氨基转移酶(FAST)评分、FIB-4和NAFLD纤维化评分(NFS)评估伴有显著纤维化的非酒精性脂肪性肝炎(NAS≥4+≥F2)。我们使用队列的80%来训练ML模型,20%来测试模型。对于≥F2、≥F3、F4以及NASH+NAS≥4+≥F2,与FibroScan、FIB-4、FAST和NFS相比,所有ML模型,尤其是RF,主要具有更高的准确性和曲线下面积(AUC)。对于≥F2、≥F3和F4,RF相对于FibroScan和FIB-4的AUC分别为(0.86对0.81、0.78),(0.89对0.83、0.82),以及(0.89对0.86、0.85)。对于NASH+NAS≥4+≥F2,RF相对于FAST、FIB-4和NFS的AUC为(0.80对0.77、0.

相似文献

1
Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis.在识别非酒精性脂肪性肝病(NAFLD)及NAFLD相关肝硬化的临床显著阶段方面,机器学习模型优于非侵入性检测。
Hepatology. 2023 Feb 1;77(2):546-557. doi: 10.1002/hep.32655. Epub 2022 Aug 9.
2
FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.在伊朗班达尔阿巴斯,比较 FIB-4、APRI 和 AST/ALT 比值与 FibroScan 用于评估非酒精性脂肪性肝病患者的肝纤维化。
BMC Gastroenterol. 2021 Dec 3;21(1):453. doi: 10.1186/s12876-021-02038-3.
3
Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.肥胖和丙氨酸氨基转移酶水平对非酒精性脂肪性肝病患者无创性工具诊断晚期肝纤维化的准确性的影响。
Am J Gastroenterol. 2019 Jun;114(6):916-928. doi: 10.14309/ajg.0000000000000153.
4
Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.临床纤维化标志物、Hepascore 和 Fibroscan®对非酒精性脂肪性肝病患者诊断肝纤维化的准确性比较。
Dig Dis Sci. 2023 Jun;68(6):2757-2767. doi: 10.1007/s10620-023-07896-3. Epub 2023 Mar 22.
5
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.非酒精性脂肪性肝病(NAFLD)合并 2 型糖尿病患者肝纤维化的无创评估。
Hepatology. 2023 Jul 1;78(1):195-211. doi: 10.1097/HEP.0000000000000351. Epub 2023 Mar 17.
6
Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.在北美队列中验证FAST™评分检测有非酒精性脂肪性肝炎(NASH)风险患者的准确性,并与其他非侵入性算法进行比较。
PLoS One. 2022 Apr 15;17(4):e0266859. doi: 10.1371/journal.pone.0266859. eCollection 2022.
7
Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.非酒精性脂肪性肝病患者肝纤维化无创评分系统评估的准确性:系统评价和荟萃分析。
Gut Liver. 2022 Nov 15;16(6):952-963. doi: 10.5009/gnl210391. Epub 2022 Feb 23.
8
The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.肝脏硬度测量值与非酒精性脂肪性肝病纤维化评分联合可提高非酒精性脂肪性肝病患者严重肝纤维化的无创性诊断准确性。
Liver Int. 2015 May;35(5):1566-73. doi: 10.1111/liv.12584. Epub 2014 May 20.
9
Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.无创性纤维化模型诊断准确性:检测纤维化分期变化。
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1877-1885.e5. doi: 10.1016/j.cgh.2018.12.031. Epub 2019 Jan 4.
10
Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).非酒精性脂肪性肝病 (NAFLD) 患者的活检率与非酒精性脂肪性肝炎 (NASH)。
Scand J Gastroenterol. 2020 Jun;55(6):706-711. doi: 10.1080/00365521.2020.1766554. Epub 2020 Jun 1.

引用本文的文献

1
Machine learning model for predicting hepatitis C seroconversion in methadone maintenance patients in China.中国美沙酮维持治疗患者丙型肝炎血清学转换预测的机器学习模型
BMJ Public Health. 2025 Aug 28;3(2):e002290. doi: 10.1136/bmjph-2024-002290. eCollection 2025.
2
Innovative machine learning approach for liver fibrosis and disease severity evaluation in MAFLD patients using MRI fat content analysis.利用MRI脂肪含量分析评估MAFLD患者肝纤维化和疾病严重程度的创新型机器学习方法。
Clin Exp Med. 2025 Aug 5;25(1):275. doi: 10.1007/s10238-025-01818-5.
3
Construction of a community-based primary screening and hospital-based confirmatory screening pathway in pediatric nonalcoholic fatty liver disease.
构建基于社区的小儿非酒精性脂肪性肝病初级筛查及基于医院的确诊筛查路径。
World J Gastroenterol. 2025 Jul 28;31(28):108321. doi: 10.3748/wjg.v31.i28.108321.
4
Application of Machine Learning Models in Predicting Non-Alcoholic Fatty Liver Disease Among Inactive Chronic Hepatitis B Patients: A Cross-Sectional Analysis.机器学习模型在预测非活动性慢性乙型肝炎患者非酒精性脂肪性肝病中的应用:一项横断面分析。
J Clin Med. 2025 Jul 16;14(14):5042. doi: 10.3390/jcm14145042.
5
Machine learning models using non-invasive tests & B-mode ultrasound to predict liver-related outcomes in metabolic dysfunction-associated steatotic liver disease.使用非侵入性检测和B超预测代谢功能障碍相关脂肪性肝病肝脏相关预后的机器学习模型
Sci Rep. 2025 Jul 8;15(1):24579. doi: 10.1038/s41598-025-09288-1.
6
The global impact of non-alcoholic fatty liver disease (including cirrhosis) in the elderly from 1990 to 2021 and future projections of disease burden.1990年至2021年非酒精性脂肪性肝病(包括肝硬化)对老年人的全球影响及疾病负担的未来预测。
PLoS One. 2025 Jun 25;20(6):e0325961. doi: 10.1371/journal.pone.0325961. eCollection 2025.
7
Liver Fat Fraction and Machine Learning Improve Steatohepatitis Diagnosis in Liver Transplant Patients.肝脏脂肪分数与机器学习改善肝移植患者的脂肪性肝炎诊断
NMR Biomed. 2025 Jul;38(7):e70077. doi: 10.1002/nbm.70077.
8
Interpretable web-based machine learning model for predicting intravenous immunoglobulin resistance in Kawasaki disease.用于预测川崎病静脉注射免疫球蛋白抵抗的基于网络的可解释机器学习模型。
Ital J Pediatr. 2025 Jun 9;51(1):181. doi: 10.1186/s13052-025-02036-1.
9
Development and Validation of Machine Learning-Based Marker for Early Detection and Prognosis Stratification of Nonalcoholic Fatty Liver Disease.基于机器学习的非酒精性脂肪性肝病早期检测和预后分层标志物的开发与验证
Adv Sci (Weinh). 2025 Sep;12(33):e10527. doi: 10.1002/advs.202410527. Epub 2025 May 28.
10
Machine Learning-Based Non-Invasive Prediction of Metabolic Dysfunction-Associated Steatohepatitis in Obese Patients: A Retrospective Study.基于机器学习的肥胖患者代谢功能障碍相关脂肪性肝炎的无创预测:一项回顾性研究。
Diagnostics (Basel). 2025 Apr 25;15(9):1096. doi: 10.3390/diagnostics15091096.